Recordati SpA (RICFY)
14.96
+2.16
(+16.93%)
USD |
OTCM |
Jun 10, 16:00
Recordati Enterprise Value : 14.46B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 14.46B |
| June 09, 2026 | 12.70B |
| June 08, 2026 | 12.69B |
| June 05, 2026 | 14.48B |
| June 04, 2026 | 14.48B |
| June 03, 2026 | 14.48B |
| June 02, 2026 | 14.48B |
| June 01, 2026 | 14.48B |
| May 29, 2026 | 14.29B |
| May 28, 2026 | 14.29B |
| May 27, 2026 | 12.55B |
| May 26, 2026 | 13.53B |
| May 22, 2026 | 10.99B |
| May 21, 2026 | 10.99B |
| May 20, 2026 | 10.99B |
| May 19, 2026 | 10.99B |
| May 18, 2026 | 11.06B |
| May 15, 2026 | 12.42B |
| May 14, 2026 | 12.69B |
| May 13, 2026 | 12.69B |
| May 12, 2026 | 12.69B |
| May 11, 2026 | 12.69B |
| May 08, 2026 | 15.24B |
| May 07, 2026 | 15.24B |
| May 06, 2026 | 15.24B |
| Date | Value |
|---|---|
| May 05, 2026 | 15.24B |
| May 04, 2026 | 15.24B |
| May 01, 2026 | 15.41B |
| April 30, 2026 | 15.41B |
| April 29, 2026 | 11.94B |
| April 28, 2026 | 12.10B |
| April 27, 2026 | 12.43B |
| April 24, 2026 | 12.43B |
| April 23, 2026 | 14.37B |
| April 22, 2026 | 14.37B |
| April 21, 2026 | 14.37B |
| April 20, 2026 | 14.37B |
| April 17, 2026 | 12.37B |
| April 16, 2026 | 12.27B |
| April 15, 2026 | 12.27B |
| April 14, 2026 | 12.08B |
| April 13, 2026 | 11.96B |
| April 10, 2026 | 11.93B |
| April 09, 2026 | 14.04B |
| April 08, 2026 | 11.84B |
| April 07, 2026 | 11.84B |
| April 06, 2026 | 14.09B |
| April 02, 2026 | 14.09B |
| April 01, 2026 | 11.95B |
| March 31, 2026 | 11.84B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DiaSorin SpA | 4.496B |
| AbbVie, Inc. | 460.94B |
| Abeona Therapeutics, Inc. | 159.71M |
| Ascentage Pharma Group International Co., Ltd. | 840.90M |
| Aardvark Therapeutics, Inc. | -14.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 179.07M |
| Revenue (Quarterly) | 834.65M |
| Total Expenses (Quarterly) | 655.58M |
| EPS Diluted (Quarterly) | 0.2141 |
| Gross Profit Margin (Quarterly) | 71.60% |
| Profit Margin (Quarterly) | 21.45% |
| Earnings Yield | 4.38% |
| Operating Earnings Yield | 7.00% |
| Normalized Earnings Yield | 4.684 |